Effects of high dose oestrogen therapy on circulating inflammatory markers

Maturitas

Volumn 62, Issue 3, 2009, Pages 281-286

  Wilson, R ^a   Spiers, A ^b   Ewan, J ^b   Johnson, P ^c   Jenkins, C ^a   Carr, S ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b Glasgow Ctr for Fam Plan/S   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cytokines; HRT; Inflammatory markers

Indexed keywords

ANTIOXIDANT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 9; CYTOKINE; ESTROGEN; LIPID;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; SEX DIFFERENCE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; CYTOKINES; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; TRANSSEXUALISM;

EID: 62849097915     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.01.009     Document Type: Article

References (27)

1. Castelli W.P. Epidemiology of coronary heart disease: the Framingham Study. Am J Med 76 (1984) 4-12
2. Grossman C.J. Regulation of the immune system by sex steroids. Endocr Rev 5 (1984) 435-455
3. Giltay E.J., Fonk J.C.M., Blomberg B.M.E., Drexhage H.A., Schalkwijk C., and Gooren L.J.G. In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. J Clin Endocrinol Metab 85 (2000) 1648-1657
4. Miller A.A., De Silva T.M., Jackman K.A., and Sobey C.G. Effect of gender and sex hormones on vascular oxidative stress. Clin Exper Pharmacol Physiol 34 (2007) 1037-1043
5. Stopinska-Gluszak U., Waligora J., Grzela T., et al. Effect of oestrogen/progesterone hormone replacement therapy on natural killer cytotoxicity and immunoregulatory cytokine release by peripheral blood mononuclear cells of postmenopausal women. J Rep Immunol 69 (2006) 65-75
6. Subbiah M.T.R. Estrogen replacement therapy and cardio protection: mechanisms and controversies. Braz J Med Biol Res 35 (2002) 271-276
7. Walsh B.W., Sciff I., Rosner B., Greenberg L., Ravnikar V., and Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Eng J Med 325 (1991) 1196-1206
8. Perez Gutthann S., Garcia-Rodriguez L.A., Castellsague J., and Duque Oliart A. Hormone replacement therapy and the risk of venous thromboembolism: population based case-control study. BMJ 314 (1997) 796-800
9. Lowe G.D. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. J Int Med 256 (2004) 361-374
10. Eilertsen A.L., Høibraaten E., Os I., Andersen O., Sandvik L., and Sandset P.M. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 52 (2005) 111-118
11. Vongpatanasin W., Tuncel M., Wang Z., Borna D., Mehrad A., and Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am College Cardiol 41 (2003) 1358-1363
12. Van Kesteren P., Lips P., Gooren L.J., Asscheman H., and Megens J. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol 48 (1998) 347-354
13. Toorians A.W.F.T., Thomassen MCLGD, Zweegman S., et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metabol 88 (2003) 5723-5729
14. New G., Timmins K.L., Duffy S.J., et al. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 29 (1997) 1437-1444
15. Wilson R., Jenkins C., Miller H., and Carr S. The effect of oestrogen on cytokine and antioxidant levels in male to female transsexual patients. Mauritas 55 (2006) 14-18
16. McCrone J.A., Walters W.A.W., Robinson J.T.C., et al. Arterial re-activity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 29 (1997) 1432-1436
17. Miller H., Wilson R., Jenkins C., Roberts J., and Walker J.J. Glutathione influences the TH1/TH2 response. Fertil Steril 74 (2000) 1257-1258
18. Crook D. The metabolic consequences of treating post-menopausal women with non-oral hormone replacement therapy. Br J Obstet Gynaecol 104 Suppl 16 (1997) pp. 4-1
19. Scarabin P.Y., Oger E., Plu-Bureau G., and and the Estrogen and ThromboEmbolism Risk (ESTHER) study group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362 (2003) 428-432
20. Sonnet E., Lacut K., Roudaut N., Mottier D., Kerlan V., and Oger E. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol 66 (2007) 626-631
21. Straub R.H., Hense H.W., Andus T., Schölmerich J., Riegger G.A.J., and Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metabol 85 (2000) 1340-1344
22. Vitale C., Gebara O., Mercuro G., et al. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk. Maturitas 50 (2005) 239-246
23. Lowe G.D.O., Upton M.N., Rumley A., McConnachie A., O'Reilly D.St.J., and Watt G.C.M. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein A cross-sectional population survey. Thromb Haemost 86 (2001) 550-556
24. Giltay E.J., Gooren L.J.G., Emeis J.J., Kooistra T., and Stehouwer C.D.A. Oral ethinyl estradiol, but not transdermal 17β-estradiol, increases plasma C-reactive protein levels in men. Thromb Haemost 84 2 (2000) 359-360
25. Miller A.A., De Silva T.M., Jackman K.A., and Sobey C.G. Effects of gender and sex hormones on vascular oxidative stress. Clin Exp Pharm Physiol 34 (2007) 1037-1043
26. Valenti S., Fazzuoli L., and Giusti M. Circulating nitric oxide levels increase after anti-androgen treatment in male-to-female transsexuals. J Endocrinol Investig 26 (2003) 522-526
27. Cicinelli E., Ignarro L.J., Schonauer L.M., Matteo G., Galantino P., and Balzano G. Effects of short-term transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertil Steril 67 (1998) 58